Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib in Prostate Cancer with Early Biochemical Failure
NCT00265070Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in prostate cancer (PCa), sponsored by AstraZeneca. Primary endpoint: Prostate Specific Antigen response rate. Started Jan 2003; status: completed.
02
Drugs
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00265070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00265070.